Periodontal Ligament Stem Cells Regulate B Lymphocyte Function via Programmed Cell Death Protein 1

Liu, Ousheng; Xu, Junji; Ding, Gang; Liu, Dayong; Fan, Zhipeng; Zhang, Chunmei; Chen, Wanjun; Ding, Yaozhong; Tang, Zhangui; Wang, Songlin

doi:10.1002/stem.1387

Cited by 83 publications

(85 citation statements)

References 49 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been demonstrated that allogeneic PDLSC transplantation into swine periodontal defect models did not induce immunorejection by showing no enhancement of T-cell and B-cell proliferation and immunoglobulin production and suggested the possibility of periodontal regeneration using allogeneic PDLSCs. 8,31 In this study, we used PDLSCs derived from relatively young donors (age, 14-28 years) and transplanted them into adult rats (7 weeks old). It is needed to take the limitation of the animal model into consideration for the estimation of the result of this study.…”

Section: Discussionmentioning

confidence: 99%

Periodontal Regeneration Using Periodontal Ligament Stem Cell-Transferred Amnion

Iwasaki

Komaki²,

Yokoyama³

et al. 2013

Tissue Engineering Part A

View full text Add to dashboard Cite

Periodontal disease is characterized by the destruction of tooth supporting tissues. Regeneration of periodontal tissues using ex vivo expanded cells has been introduced and studied, although appropriate methodology has not yet been established. We developed a novel cell transplant method for periodontal regeneration using periodontal ligament stem cell (PDLSC)-transferred amniotic membrane (PDLSC-amnion). The aim of this study was to investigate the regenerative potential of PDLSC-amnion in a rat periodontal defect model. Cultured PDLSCs were transferred onto amniotic membranes using a glass substrate treated with polyethylene glycol and photolithography. The properties of PDLSCs were investigated by flow cytometry and in vitro differentiation. PDLSC-amnion was transplanted into surgically created periodontal defects in rat maxillary molars. Periodontal regeneration was evaluated by microcomputed tomography (micro-CT) and histological analysis. PDLSCs showed mesenchymal stem cell-like characteristics such as cell surface marker expression (CD90, CD44, CD73, CD105, CD146, and STRO-1) and trilineage differentiation ability (i.e., into osteoblasts, adipocytes, and chondrocytes). PDLSC-amnion exhibited a single layer of PDLSCs on the amniotic membrane and stability of the sheet even with movement and deformation caused by surgical instruments. We observed that the PDLSC-amnion enhanced periodontal tissue regeneration as determined by micro-CT and histology by 4 weeks after transplantation. These data suggest that PDLSC-amnion has therapeutic potential as a novel cell-based regenerative periodontal therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Periodontal Regeneration Using Periodontal Ligament Stem Cell-Transferred Amnion

Iwasaki

Komaki²,

Yokoyama³

et al. 2013

Tissue Engineering Part A

View full text Add to dashboard Cite

show abstract

“…Based on these findings, human autologous MSCs have been successfully used in the clinical treatment of long bone defects and osteonecrosis of the femoral head (Garg et al , ; Sim et al , ; Chapman et al , ; Connolly, ; Kawate et al , ). In addition, allogeneic MSCs derived from adipose tissue and dental tissue have the capacity to regenerate bone without the need for immunosuppressive therapy and show similar regenerative effects to those observed in autologous MSC implantation (Ding et al , ; Liu et al , ,b). Nevertheless, although a variety of literature reports have shown the efficacy and safety of using MSCs for bone regeneration, no such use has yet been approved by the US Food and Drug Administration (FDA).…”

Section: Mscs In Cell‐based Bone Regenerationmentioning

confidence: 96%

Immunomodulation regulates mesenchymal stem cell‐based bone regeneration

Shi

Liu

2014

Oral Diseases

View full text Add to dashboard Cite

Mesenchymal stem cell (MSC)-based regenerative medicine represents a promising frontier for bone reconstruction. Significant efforts have been devoted to clarifying the capacities of MSCs to repair or reconstruct bone tissue. This review provides a concise summary of current knowledge pertaining to the possible mechanisms of MSC action in the regeneration of bone, with particular focus on the interplay between donor MSCs and host immune response in the process of new bone regeneration.

show abstract

“…Additionally, there is data suggesting that MSCs suppress B cells through PDL1/PD1 pathway [102]. Another study by Liu et al demonstrates that periodontal ligament stem cells inhibit B cell activation through PDL1/PD1 [103]. These results suggest that stem cells act on the humoral immune responses through the PDL1/PD1 pathway.…”

Section: Common Snps In the Immunoregulatory Pathways Of Msc's Intmentioning

confidence: 99%

From Single Nucleotide Polymorphisms to Constant Immunosuppression: Mesenchymal Stem Cell Therapy for Autoimmune Diseases

Chinnadurai

Waller

Galipeau

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

The regenerative abilities and the immunosuppressive properties of mesenchymal stromal cells (MSCs) make them potentially the ideal cellular product of choice for treatment of autoimmune and other immune mediated disorders. Although the usefulness of MSCs for therapeutic applications is in early phases, their potential clinical use remains of great interest. Current clinical evidence of use of MSCs from both autologous and allogeneic sources to treat autoimmune disorders confers conflicting clinical benefit outcomes. These varied results may possibly be due to MSC use across wide range of autoimmune disorders with clinical heterogeneity or due to variability of the cellular product. In the light of recent genome wide association studies (GWAS), linking predisposition of autoimmune diseases to single nucleotide polymorphisms (SNPs) in the susceptible genetic loci, the clinical relevance of MSCs possessing SNPs in the critical effector molecules of immunosuppression is largely undiscussed. It is of further interest in the allogeneic setting, where SNPs in the target pathway of MSC's intervention may also modulate clinical outcome. In the present review, we have discussed the known critical SNPs predisposing to disease susceptibility in various autoimmune diseases and their significance in the immunomodulatory properties of MSCs.

show abstract

Periodontal Ligament Stem Cells Regulate B Lymphocyte Function via Programmed Cell Death Protein 1

Cited by 83 publications

References 49 publications

Periodontal Regeneration Using Periodontal Ligament Stem Cell-Transferred Amnion

Periodontal Regeneration Using Periodontal Ligament Stem Cell-Transferred Amnion

Immunomodulation regulates mesenchymal stem cell‐based bone regeneration

From Single Nucleotide Polymorphisms to Constant Immunosuppression: Mesenchymal Stem Cell Therapy for Autoimmune Diseases

Contact Info

Product

Resources

About